João Pisco1, Tiago Bilhim2, Luis C Pinheiro3, Lúcia Fernandes2, José Pereira2, Nuno V Costa2, Marisa Duarte4, António G Oliveira5. 1. Interventional Radiology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal. Electronic address: martinspisco@hslouis.pt. 2. Interventional Radiology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal; Radiology Department, Medicine Faculty, Universidade Nova de Lisboa, Lisbon, Portugal. 3. Urology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal. 4. Interventional Radiology Department, Hospital Saint Louis, R. Luz Soriano, Lisbon 1200-249, Portugal. 5. Biostatistics Department and Department of Pharmacy, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brasil.
Abstract
PURPOSE: To evaluate efficacy of prostate artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH), prostate volume (PV) > 100 cm(3). MATERIALS AND METHODS: This was a single-center retrospective cohort study. Between March 2009 and September 2014, PAE was performed in patients with a diagnosis of BPH, PV > 100 cm(3), and moderate to severe lower urinary tract symptoms (LUTS) refractory to medical treatment for at least 6 months or who had acute urinary retention. Success was defined as improved symptoms (International Prostate Symptom Score ≤ 15 and decrease of ≥ 25% from baseline score), improved quality of life (measured as score of ≤ 3 points or decrease of ≥ 1 point from baseline), and no need for additional treatment. RESULTS: PAE was performed in 152 patients 48-87 years old (mean ± SD 67.4 y ± 7.5) with mean PV of 134.2 cm(3) ± 41.8 (range, 101-383 cm(3)). PAE was technically successful in 149 patients (98.0%). Symptomatic control was achieved for a median of 18 months ± 15.5 (range, 3-66 mo). There were 33 clinical failures (23.6%); 23 occurred in the short-term (≤ 6 mo), and 10 occurred in the medium-term (6-24 mo); there were no long-term failures (> 36 mo). Cumulative clinical success rates were 90%, 87.9%, 83.5%, 81.1%, and 77.8% at 1, 3, 6, 12, and 18 months and 72.4% thereafter to 66 months (5.5 y). CONCLUSIONS: PAE provides sustained short-, medium-, and long-term control for LUTS in patients with BPH and PV > 100 cm(3).
PURPOSE: To evaluate efficacy of prostate artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH), prostate volume (PV) > 100 cm(3). MATERIALS AND METHODS: This was a single-center retrospective cohort study. Between March 2009 and September 2014, PAE was performed in patients with a diagnosis of BPH, PV > 100 cm(3), and moderate to severe lower urinary tract symptoms (LUTS) refractory to medical treatment for at least 6 months or who had acute urinary retention. Success was defined as improved symptoms (International Prostate Symptom Score ≤ 15 and decrease of ≥ 25% from baseline score), improved quality of life (measured as score of ≤ 3 points or decrease of ≥ 1 point from baseline), and no need for additional treatment. RESULTS:PAE was performed in 152 patients 48-87 years old (mean ± SD 67.4 y ± 7.5) with mean PV of 134.2 cm(3) ± 41.8 (range, 101-383 cm(3)). PAE was technically successful in 149 patients (98.0%). Symptomatic control was achieved for a median of 18 months ± 15.5 (range, 3-66 mo). There were 33 clinical failures (23.6%); 23 occurred in the short-term (≤ 6 mo), and 10 occurred in the medium-term (6-24 mo); there were no long-term failures (> 36 mo). Cumulative clinical success rates were 90%, 87.9%, 83.5%, 81.1%, and 77.8% at 1, 3, 6, 12, and 18 months and 72.4% thereafter to 66 months (5.5 y). CONCLUSIONS:PAE provides sustained short-, medium-, and long-term control for LUTS in patients with BPH and PV > 100 cm(3).
Authors: Alexander S Somwaru; Stephen Metting; Laura M Flisnik; Michael G Nellamattathil; Arjun Sharma; Venkat S Katabathina Journal: BMC Urol Date: 2020-10-08 Impact factor: 2.264
Authors: Vanessa F Schmidt; Mirjam Schirren; Maurice M Heimer; Philipp M Kazmierczak; Clemens C Cyran; Moritz Wildgruber; Max Seidensticker; Jens Ricke; Olga Solyanik Journal: Diagnostics (Basel) Date: 2022-02-25